Skip to content
Peptide Insider

Dual GIP and GLP-1 receptor agonist

Tirzepatide

Also known as Mounjaro · Zepbound · LY3298176 · GIP/GLP-1 receptor agonist

FDA ApprovedCLINICALFDA approved: Yes

Tirzepatide activates two incretin receptors rather than one: the GLP-1 receptor, familiar from semaglutide, and the receptor for glucose-dependent insulinotropic polypeptide (GIP). The rationale is that the incretin effect in healthy physiology is produced by both hormones acting together, so a single-receptor drug reproduces only part of it. That reasoning turned out to be productive. Tirzepatide produced larger mean weight reductions than had been seen with GLP-1 agonism alone, and it went on to earn an approval no other obesity drug holds — for moderate to severe obstructive sleep apnoea in adults with obesity. For a site concerned with evidence quality, tirzepatide is a useful case: a mechanistic hypothesis that was tested properly and turned out to be right.

Written by Peptide Insider Editorial TeamPublished Last reviewed

The Insider Summary

What it is
A single 39-amino-acid peptide that activates both the GIP and GLP-1 receptors, engineered with a fatty diacid chain for once-weekly dosing.
Why researchers are interested
Dual incretin agonism produced greater weight reduction than GLP-1 agonism alone in head-to-head and placebo-controlled trials, and the programme extended into a non-metabolic clinical endpoint — sleep apnoea severity — with a successful result.
Evidence
Clinical. Large randomised controlled trials across the SURPASS (diabetes) and SURMOUNT (obesity) programmes, with published results and hard regulatory review.
Regulatory status
FDA approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and for moderate to severe obstructive sleep apnoea in adults with obesity. Carries a boxed warning for thyroid C-cell tumours.
Bottom line
Tirzepatide is the strongest current demonstration that adding receptor targets can add clinical effect — which is precisely the logic behind the triple agonists now in development. It is also a reminder that the way to establish this is a pivotal trial programme, not a mechanism diagram.

Quick reference

Compound
Synthetic peptide agonist
Research areas
Metabolic Research
Evidence level
CLINICAL
Research status
FDA Approved
FDA approved
Yes — for type 2 diabetes (as Mounjaro); chronic weight management and long-term weight maintenance in adults with obesity, or overweight with at least one weight-related comorbidity (as Zepbound); moderate to severe obstructive sleep apnoea in adults with obesity (as Zepbound)
Human clinical evidence
Extensive
Sequence
A 39-amino-acid synthetic peptide based on the GIP sequence, acylated with a C20 fatty diacid for albumin binding.
Last reviewed
17 September 2026

What is tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide built on the GIP sequence and engineered to activate two receptors at once. It is sometimes called a "twincretin" for that reason.

Incretins are gut hormones released in response to food that amplify insulin secretion. Two dominate: GLP-1 and GIP. Drug development concentrated on GLP-1 first, partly because the GIP response is blunted in type 2 diabetes and GIP agonism was considered unpromising. Tirzepatide's success complicated that picture, and the mechanistic explanation for why dual agonism outperforms is still being worked out.

That is worth stating plainly, because it cuts against a common assumption: a drug can have clearly demonstrated clinical effects while its mechanism remains partly unresolved. Clinical evidence and mechanistic understanding are separate things, and the former is what regulators approve on.

What is tirzepatide approved for?

As of the January 2026 revision of the Zepbound prescribing information, Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity [1]:

  • to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition;
  • to treat moderate to severe obstructive sleep apnoea in adults with obesity.

Tirzepatide is separately approved as Mounjaro for type 2 diabetes.

The sleep apnoea indication is notable: it was the first approval of any drug for obstructive sleep apnoea, and it was earned through dedicated trials with polysomnography-based endpoints rather than inferred from weight loss.

How does Tirzepatide work?

Tirzepatide is a single molecule with agonist activity at both the GIP receptor and the GLP-1 receptor, with greater relative potency at GIP. GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional insulinotropic effect and appears to act on adipose tissue and central appetite pathways; its precise contribution to weight reduction remains an active research question rather than a settled one. A C20 fatty diacid chain enables albumin binding and once-weekly administration.

Research and clinical evidence

The table below grades the published record separately for each research area, because a compound can be well studied in one context and entirely unstudied in another. Grades follow the Peptide Insider evidence taxonomy.

Evidence level by research area
Research areaEvidence levelWhat the published record shows
Chronic weight managementCLINICALThe SURMOUNT programme demonstrated large, dose-dependent mean weight reductions versus placebo over 72 weeks.
Type 2 diabetesCLINICALThe SURPASS programme established glycaemic efficacy supporting approval as Mounjaro.
Obstructive sleep apnoea in adults with obesityCLINICALDedicated randomised trials with apnoea–hypopnoea index endpoints supported the first FDA approval of a drug for this condition.
Cardiovascular outcomesEARLY CLINICALDedicated cardiovascular outcomes evidence for tirzepatide is less mature than for semaglutide. Readers should check the current label rather than assume class equivalence.

Human clinical studies

Studies conducted in people. These carry the most weight, and their absence is itself a finding.

Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)[2]

2022
Design
Randomised, double-blind, placebo-controlled, 72 weeks
Population
Adults with obesity, or overweight with at least one weight-related complication, without diabetes
Subjects
Approximately 2,539 randomised

FindingsMean percentage weight reduction of approximately 16.0% to 22.5% across the 5 mg, 10 mg and 15 mg doses at 72 weeks, substantially greater than placebo.

LimitationsWeight change is the primary endpoint; the trial was not designed to measure cardiovascular or mortality outcomes. Gastrointestinal adverse events were common and dose-related. Participants without diabetes — results do not transfer directly to other populations.

FDA and regulatory status

Tirzepatide is FDA approved, with indications specific to each product.

The Zepbound prescribing information carries a boxed warning for risk of thyroid C-cell tumours: tirzepatide causes thyroid C-cell tumours in rats at clinically relevant exposures, and the human risk is unknown. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].

As with semaglutide, compounded tirzepatide is not the approved product. It has not been through FDA review for safety, efficacy or manufacturing quality.

Safety and known risks

Risks are separated into what is documented, what is plausible but unestablished, and what has not been studied. The third column is usually the longest one for an unapproved compound, and it is not a reassurance.

Known risks

Documented in regulatory labelling or published trial safety data.

  • Boxed warning for risk of thyroid C-cell tumours, based on rat findings; human relevance unknown.
  • Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
  • Gastrointestinal adverse effects — nausea, diarrhoea, vomiting, constipation — are common and dose-related.
  • Labelled warnings include pancreatitis, gallbladder disease, acute kidney injury from volume depletion, hypersensitivity reactions and diabetic retinopathy complications.
  • Hypoglycaemia risk when combined with insulin or insulin secretagogues.

Potential risks

Plausible on mechanism or drug-class grounds, but not established for this compound.

  • Body-composition effects during rapid weight loss, including lean mass, remain under active study.
  • Durability after discontinuation, and the implications for treatment duration.

Unknown or insufficiently studied

Questions the published record does not currently answer.

  • Multi-decade safety is not yet characterised for any drug in this class.
  • The precise contribution of GIP receptor agonism to the observed clinical effects.

Frequently asked questions

What is the difference between tirzepatide and semaglutide?
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors. In trials, tirzepatide produced larger mean weight reductions. Their approved indications also differ — tirzepatide is approved for obstructive sleep apnoea in adults with obesity, semaglutide for cardiovascular risk reduction and for MASH with F2–F3 fibrosis.
Is tirzepatide approved for sleep apnoea?
Yes — Zepbound is indicated for moderate to severe obstructive sleep apnoea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity. It was the first drug approved for this condition.[1]
How much weight did people lose in the trials?
In SURMOUNT-1, mean weight reduction at 72 weeks was approximately 16.0% to 22.5% depending on dose, compared with a much smaller reduction on placebo. Trial averages describe a group, not an individual outcome.[2]
Does tirzepatide have a boxed warning?
Yes — for risk of thyroid C-cell tumours, based on findings in rats at clinically relevant exposures. Human risk is unknown, and the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.[1]

Continue reading

Comparison

Semaglutide vs Tirzepatide vs Retatrutide

One, two and three receptors. Two approved drugs and one investigational compound. What the trials measured, what the labels say, and where the differences actually lie.

Regulation

Are Peptides FDA Approved?

Some peptides are FDA approved drugs. Most compounds sold as "peptides" are not. Here is how to tell the difference, and what approval does and does not mean.

Regulation

Investigational vs Approved Peptides

Investigational, approved, discontinued and unstudied are four different states, and compounds in all four are sold side by side. How to tell them apart.

References

Peptide Insider cites primary sources wherever they exist — regulatory documents, trial registrations and peer-reviewed literature — in preference to secondary summaries.

  1. 1.
    U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) — Highlights of Prescribing Information. FDA Drugs@FDA, 2026;NDA 217806, label revised 01/2026.
    Regulatory
  2. 2.
    Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 2022;387(3):205–216.
    Peer-reviewedDOI: 10.1056/NEJMoa2206038PMID: 35658024